TrialJournal of Crohn's & colitis2026

Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE).

Jagoda Pokryszka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.